CD8A and neoplasm: Given the regulatory role of the TIGIT pathway in T cell and NK cell-mediated tumor recognition, dual blockade of PD-1 and TIGIT effectively increases the expansion of tumor antigen-specific CD8+ T cells in vitro, promoting tumor rejection in a mouse model [181].